<DOC>
	<DOCNO>NCT00095433</DOCNO>
	<brief_summary>This Phase III , open-label , multicenter extension study intravitreally administer ranibizumab subject primary recurrent subfoveal choroidal neovascularization ( CNV ) secondary AMD complete treatment phase Genentech sponsor Phase I Phase I/II ranibizumab protocol ( FVF1770g , FVF2128g , FVF2425g ) .</brief_summary>
	<brief_title>Extension Study rhuFab V2 Subjects With Neovascular Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent authorization use disclosure protect health information Age &gt; =50 year Completion treatment phase Genentech sponsor Phase I I/II ranibizumab protocol ( FVF1770g , FVF2128g , FVF2425g ) CNV either eye due cause ocular histoplasmosis , trauma , pathologic myopia Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye Subretinal hemorrhage study eye involve fovea , size hemorrhage either &gt; =50 % total lesion area &gt; =1 DA size Intraocular surgery ( include cataract surgery ) study eye within 1 month precede Week 0 Uncontrolled glaucoma study eye ( defined intraocular pressure &gt; =30 mmHg despite treatment antiglaucoma medication ) Premenopausal woman use adequate contraception Laser photocoagulation ( subfoveal , juxtafoveal , extrafoveal ) study eye within 30 day precede Week 0 Prior treatment externalbeam radiation therapy transpupillary thermotherapy ( TTT ) study eye Previous treatment verteporfin study eye within 30 day precede Week 0 Treatment verteporfin nonstudy eye within 7 day precede Week 0 History vitrectomy , submacular surgery , surgical intervention AMD study eye Previous participation clinical trial ( either eye ) involve antiangiogenic drug ranibizumab ( e.g. , pegaptanib , anecortave acetate , protein kinase C inhibitor , etc . ) Previous participation study investigational drug within 1 month precede Week 0 ( exclude vitamin mineral study ) Discontinuation ranibizumab study due adverse event judge investigator possibly probably related ranibizumab History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>AMD</keyword>
	<keyword>Neovascular age-related macular degeneration</keyword>
</DOC>